SAILIFESai Life Sciences Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassWatch
Market Cap₹21,380 Cr
Primary DriverGrowth Sustainability
Flagium AI Risk Score
Early signs of stress detected. Not yet widespread, but initial deterioration is visible.
25 / 100
-5 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in growth sustainability. This suggests the risk profile is currently stabilizing. Risk levels are improving.

65.7th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹1,128.3▼1.48%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Growth Sustainability
+10.0 pts
Stability Adjustment
+15.0 pts
Final Composite Risk25 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 25 over 12 quarters.

Expected Direction
🟢 Improving
Primary Deterioration Drivers
  • Inventory Stress
  • Industrial Margin Stress
  • Working Capital Expansion
What to Watch Next Quarter
  • Working capital efficiency
  • Operating profit margins
  • Inventory turnover

Active Risk Objects (4)

CriticalHigh
Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ2 FY2026
Working capital expansion detected: Receivable days increased by 434.0%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Capex Efficiency Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight8/15
MomentumAccelerating
Last SignalQ2 FY2026
Aggressive Capex (44.8%) amidst slow revenue growth (-75.3%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ4 FY2026
Inventory growth (27.0%) significantly outpaced revenue growth (4.8%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Industrial Margin Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight12/15
MomentumAccelerating
Last SignalQ2 FY2026
SAILIFE: Raw material costs consumed an additional 10.2% of revenue YoY.

"Margins are in freefall. Operating costs are growing significantly faster than revenue."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)4.647.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+41.0+47.0📈 CRITICAL
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹1,128.3(-1.48%)
1M Divergence+3.24%
1 Week-1.11%
1 Month+5.5%
6 Months+30.06%
1 Year+55.83%
2 Year+50.2%
3 Year+50.2%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The risk profile is Early Signals and currently improving. Recent structural triggers in growth sustainability suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Initial structural recovery is visible; monitor for a sustained return to resilience.

SAILIFE • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.95%
Trend QualityStrong
Phase Progression
Phase Progression Score82.5%
Readiness LabelHigh (Phase Transition Imminent)
Probability of Advancing95%
CoinTree Momentum
Composite Z-Score+0.3913σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#516 of 2716
Top 19.00% in momentum strength
Timeframe Sparklines
1W-1.1%
1M+5.5%
6M+30.1%
Weinstein Indicators
150 DMA₹953.51
200 DMA₹933.53
150 DMA Slope+3.5832%Rising
Relative Strength+35.55%Leading
Relative Turnover (RTR)1.1807
ParticipationNeutral

PEER COMPARISON

Ranked comparison against sector peers

This company shows higher risk compared to the Sector Mean (19).
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

SAILIFESai Life Sciences Limited
25 Risk
Sector %ile66th
Delta-5
Active Flags4
Accel+0
Growth Sustainability

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

BALAXIBALAXI PHARMACEUTICALS LIMITED
45 Risk
Sector %ile96th
Delta+10
Active Flags40
Accel+1
Balance Sheet Stress

Moderate Deterioration

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
00th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Inventory Stress

2026

Industrial Margin Stress

2026

Working Capital Expansion

2026

Capex Efficiency Stress

2026

Industrial Margin Stress

2025

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20262,24234950995
FY20251,731170314129